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H5N1 highly pathogenic avian influenza virus has been endemic in poultry in Egypt since 2008, notwith-
standing the implementation of mass vaccination and culling of infected birds. Extensive circulation of the
virus has resulted in a progressive genetic evolution and an antigenic drift. In poultry, the occurrence of
antigenic drift in avian influenza viruses is less well documented and the mechanisms remain to be clarified.
To test the hypothesis that H5N1 antigenic drift is driven by mechanisms similar to type A influenza viruses
in humans, we generated reassortant viruses, by reverse genetics, that harbored molecular changes identified
in genetically divergent viruses circulating in the vaccinated population. Parental and reassortant phenotype
viruses were antigenically analyzed by hemagglutination inhibition (HI) test and microneutralization (MN)
assay. The results of the study indicate that the antigenic drift of H5N1 in poultry is driven by multiple
mutations primarily occurring in major antigenic sites at the receptor binding subdomain, similarly to what
has been described for human influenza H1 and H3 subtype viruses.
The highly pathogenic avian influenza (HPAI) viruses be-
longing to the H5N1 subtype emerged for the first time in
Southeast China in 1996. After its reemergence in China in
2003, the virus rapidly spread to other Asian countries first and
then to Europe and Africa. Its continuous circulation in the
animal reservoir has led to a significant genetic diversification
represented by multiple phylogenetic lineages, classified as
clades 0 to 9 (4, 37).
Egypt officially reported its first outbreak in poultry in Feb-
ruary 2006 (http://www.oie.int/eng/info_ev/en_AI_factoids_H5N1
_Timeline.htm). Since then, clade 2.2 viruses have spread
among domesticated birds throughout the country and
HPAI H5N1 virus was declared endemic in Egypt in
July 2008 (http://www.oie.int/animal-health-in-the-world
/web-portal-on-avian-influenza/about-ai/h5n1-timeline/). The epi-
demic resulted in disruption of the national poultry industry
and in severe economic losses. In addition, the continuous
circulation of this virus in the environment has increased the
risk of human exposure. Indeed, bird-to-human transmissions
with severe public health consequences have been occurring in
Egypt since 2006, causing 125 human cases and 41 fatalities to
date (28 February 2011; http://www.who.int/csr/disease/avian
_influenza/country/cases_table_2011_02_28/en/index.html).
With the aim of reducing the risk for humans and the eco-
nomic losses to industry, major interventions were taken by the
veterinary services to control the epidemic in poultry. In the
first period of the epidemic, these interventions were based on
the culling of infected birds and movement restrictions (2, 28).
Subsequently, mass vaccination in poultry was introduced of-
ficially both in the industrial sector and in backyard flocks in
March 2006 and May 2007, respectively. As a consequence of
the many practical difficulties in vaccinating poultry in the field,
particularly household flocks, the vaccine coverage is very low
in Egypt with an average of 25 to 30% in some governatorates,
dropping to as low as 1% in some villages. Even in commercial
flocks, vaccine coverage of only 50 to 60% is a realistic estimate
(28).
Despite all the control measures taken, the virus continues
to circulate in poultry in both vaccinated commercial and back-
yard flocks (10). As a result of this persistent circulation, the
HPAI H5N1 viruses have evolved and progressively diverged
to the extent that they are currently reclassified as a third-order
genetic clade, namely, clade 2.2.1 (3, 37).
By late 2007 and early 2008, clade 2.2.1 viruses emerged in
Egypt (1, 2, 19) and showed genetically and antigenically dis-
tinguishable features. These emerging viruses have not re-
placed the previous circulating strains but are instead cocircu-
lating with them in poultry. The hemagglutinin (HA) sequence
of these viruses is grouped in a separate branch within clade
2.2.1 of the phylogenetic tree (see Fig. S1 in the supplemental
material). Accumulation of amino acid (AA) mutations in
the major antigen, the HA protein, has raised concerns
about the efficacy of “in-field” vaccination of poultry. In
addition, in the light of this evolving situation the World
Health Organization (WHO) has recently revised the pro-
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posed 2.2.1 strains as candidates for the development of
human vaccines (39).
In order to control the infection in poultry, different types of
inactivated avian influenza (AI) virus vaccines have been im-
ported and applied in Egypt. Vaccine strains are represented
by “homologous” H5N1 subtypes (e.g., mostly H5N1 Re-1
Chinese vaccines) and are predominantly used in household
poultry. Mexican-derived A/H5N2 vaccines are most commonly
applied in commercial poultry farms (29). Before being re-
leased on the market, all imported vaccines are evaluated ac-
cording to international standards for vaccine quality assur-
ance. For potency testing, vaccines are challenged against
Egyptian H5N1 isolates (29). At the time of writing, the strain
used for official challenge testing in Egypt is an early 2008
isolate belonging to a genetically distinguishable group of vi-
ruses that emerged in the country (in this work, this challenge
strain is named 1709-6/2008).
Compared to the previously circulating strains (2006 to
2007), a lower level of antigenic cross-reactivity was revealed
by HI testing between the selected 2008 challenge strain and
the Mexican-derived H5N2 vaccine strain, indicating a signif-
icant vaccine drift (35). Interestingly, this lower cross-reactivity
did not adequately predict the clinical protection induced by
the vaccine in challenged chickens. In fact, 80% protection was







1 2 3 4 5 6 7 8 9 1709-6/08
1709-
1/07
1 A/Ck/Eg1709-6/08 stock L.39/08 4 0 4 8 64 2 32 4 4 4 1,024 256
2 A/Ck/Eg1709-1/07 stock L.41/08 256 64 128 256 512 128 512 128 512 362 512 1,024
3 RG PR8Eg6 HANA 4 0 4 8 64 4 32 4 4 4 1,024 256
4 RG PR8Eg1 HANA 128 64 128 512 512 256 512 128 512 256 1,024 2,048
5 RG PR8Eg6 HANA S74P 32 16 64 64 256 32 256 64 64 45
6 RG PR8Eg1 HANA P74S 128 64 128 128 512 256 512 256 512 256
7 RG PR8Eg6 HANA G140R 4 4 4 16 128 64 256 16 256 32
8 RG PR8Eg1 HANA R140G 512 128 128 512 512 128 1,024 128 256 362
9 RG PR8Eg6 HANA S74P G140R 8 8 8 16 256 64 128 32 128 32
10 RG PR8Eg1 HANA P74S R140G 256 256 256 128 256 128 512 2,048 256 256
11 RG PR8Eg6 HANA S74P P141S 32 8 8 16 256 16 128 16 64 45
12 RG PR8Eg1 HANA P74S S141P 32 32 32 128 256 128 512 128 256 91
13 RG PR8Eg6 HANA S74P G140R P141S 32 16 32 64 1,024 64 256 64 256 91
14 RG PR8Eg1 HANA P74S R140G S141P 64 64 64 128 128 64 512 64 64 64
15 RG PR8Eg6 HANA G140R P141S Y144F 32 16 16 32 512 64 256 64 256 91
16 RG PR8Eg1 HANA R140G S141P F144Y 64 32 32 64 64 32 256 64 64 64
17 RG PR8Eg6 HANA S74P G140R P141S
Y144F
128 32 128 128 1,024 256 1,024 256 1,024 362
18 RG PR8Eg1 HANA P74S R140G S141P
F144Y
64 64 64 128 128 64 256 64 64 64
19 RG PR8Eg6 HANA S74P G140R P141S
Y144F K162R
64 32 64 128 512 256 512 64 512 181
20 RG PR8Eg1 HANA P74S R140G S141P
F144Y R162K
8 8 16 16 32 8 64 4 8 8
21 RG PR8Eg6 HANA S74P G140R P141S
K162R
32 16 64 64 512 128 256 64 512 128
22 RG PR8Eg1 HANA P74S R140G S141P
R162K
16 16 64 32 256 32 16 16 16 16
23 RG PR8Eg6 HANA S74P R110H G140R
P141S Y144F
64 32 128 128 1,024 256 512 128 1,024 256
24 RG PR8Eg1 HANA P74S H110R R140G
S141P F144Y
64 64 64 128 128 32 256 32 32 45
25 RG PR8Eg6 HANA S74P S120N G140R
P141S Y144F
128 64 256 256 2,048 512 512 128 1,024 362
26 RG PR8Eg1 HANA P74S N120S R140G
S141P F144Y
64 64 64 128 128 64 256 64 64 64
27 RG PR8Eg1 HANA P74S N120S R140G
S141P F144Y R162K A184E
4 4 16 32 128 8 64 8 16 8
28 RG PR8Eg1 HANA P74S R140G S141P
F144Y R162K A184E
16 8 64 64 1,024 32 128 16 16 16
29 RG PR8Eg1 HANA P74S R140G S141P
F144Y A184E
32 16 32 64 128 32 256 32 16 23
30 RG PR8Eg1 HANA R140G S141P F144Y
R162K
32 32 64 32 128 32 128 16 64 45
31 RG PR8Eg1 HANA N120S R140G S141P
F144Y R162K A184E
32 16 32 64 256 32 128 32 64 45
32 RG PR8Eg1 HANA R140G S141P F144Y
A184E
64 64 64 128 128 64 512 64 64 64
33 RG PR8Eg1 HANA N120S R140G S141P
F144Y
128 64 64 128 128 64 256 64 64 91
34 RG PR8Eg1 HANA N120S R140G S141P
F144Y A184E
128 32 64 128 128 64 256 64 64 91
35 A/Ck/Mex/232/94b 2,048 4,096 4,096 4,096 4,096 1,024 2,048 2,048 4,096 3,010
a The stock and mutant viruses created (1 to 34) were tested by HI assay against avian sera of chickens vaccinated with the Mexican-derived H5N2 strain (sera 1 to
9). The HI titers of sera 1 to 9 were used to calculate the mean geometric titers (MGTs). Strains 1 to 4 were tested by cross-HI against avian sera homologous to the
field strains (sera 1709-1/07 and 1709-6/08).
b Homologous vaccine strain A/chicken/Mexico/232/94.
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achieved after challenge with 1709-6/2008, and viral shedding
was significantly reduced (35). Similar results were obtained in
chickens immunized with the same vaccine and challenged
with a distinct 2008 Egyptian strain (19).
There is scientific evidence indicating that evolution and
antigenic drift of human influenza (H1 and H3 influenza A)
viruses are driven by multiple mutations within major antigenic
sites of HA located in the receptor binding subdomain (RBD)
(11, 32). In poultry, the occurrence of antigenic drift in avian
influenza viruses is less well documented and the mechanisms
remain to be clarified, particularly with reference to the use of
vaccines as control measures for HPAI epidemics. Antigenic
drift was demonstrated in Mexico for H5N2 viruses causing a
low-pathogenic AI epidemic; however, its association with vac-
cination in poultry was not clearly established (22). Although
antigenic diversity has been described for H5N1 HPAI viruses
in Asia and in Egypt (2, 40), its driving mechanisms and the
impact on control measures have not yet been established.
To test the hypothesis that HPAI H5N1 virus antigenic drift
is driven by mechanisms similar to type A influenza viruses in
humans, the molecular changes in genetically divergent vi-
ruses circulating among vaccinated poultry in Egypt have
been mapped and antigenically analyzed in this study. In ad-
dition, this study aims to clarify the correlation of hemagglu-
tination inhibition (HI) and microneutralization (MN) test re-
sults with vaccine efficacy prediction in poultry. This type of
data will provide information for a better selection of vaccine
strains and vaccine strategies.
MATERIALS AND METHODS
Virus strains used in this study and generation of recombinant viruses. Viral
strains included in this study, namely, 1709-1/2007 (GenBank accession number
EU717849) and 1709-6/2008 (GenBank accession number EU717857), were
isolated by the Animal Health Research Institute in Egypt (AHRI-NLQP, Giza,
Egypt). Viruses were obtained from samples collected in commercial poultry
flocks on 25 February 2007 and 3 January 2008, respectively. Strain 1709-6/2008
is the challenge virus applied in Egypt at the time of writing and also used in a
previous challenge study (35). Based on its position in the phylogenetic tree (see
Fig. S1 in the supplemental material), this strain could be considered one of the
earliest genetically distinct viruses that emerged in Egypt by late 2007 to early
2008. Compared to the Mexican-derived H5N2 vaccine strain, the analyzed AA
sequence of the HA protein of 1709-1/2007 was considered representative of the
H5N1 viruses circulating in Egypt before the emergence of the distinct group of
viruses in late 2007. In fact, the AA differences between 1709-1/2007 and the
vaccine strain were common to the vast majority of the 157 H5N1 Egyptian HA
sequences (2006 to 2007) downloaded from the public database (GenBank) and
analyzed for this study (data not shown).
Reassortant viruses containing the HA and NA of the H5N1 strains in a
genetic background of A/PR/8/34 (H1N1) were generated by reverse genetics
(RG) as described previously (13). Mutations of interest in the HA gene were
introduced by PCR using the QuikChange Site-Directed Mutagenesis kit (Strat-
agene). The whole-genome sequence of the parental viruses and the full-length
HA gene sequences of the RG reassortants were confirmed by sequence analysis
of the cDNA amplified from viral RNA by reverse transcription-PCR (RT-PCR).
Serological tests. HI and MN assays were applied to evaluate the immune
response to the vaccine. Sera containing antibodies to the H5N2 vaccine strain
(A/chicken/Mexico/232/94) were obtained from specific-pathogen-free (SPF)
chickens vaccinated at 21 days of age and boosted after 3 weeks with a commer-
cially available vaccine, which had been used in previous studies (19, 35). The HI
assay was performed according to the international standard procedure (27) for
testing avian sera using parental and reassortant viruses as antigens (4 hemag-
glutination units [HAU]).
The serum neutralizing activity was assessed by a standard MN assay per-
formed as previously described (31). Avian sera were treated with a receptor-
destroying enzyme (RDE) before use and heat inactivated at 56°C for 30 min.
Sera raised against homologous antigens (i.e., 1709-1/2007 and 1709-6/2008), one
unrelated avian influenza virus antigen (H7N1/HPAI), and one negative chicken
serum were included in the assay as controls.
RESULTS
Serology on field (parental) strains. Table 1 and Table 2
report serological results obtained using the HI and MN assays
performed on field strains 1709-1/2007 and 1709-6/2008. A signif-
icant reduction, in some sera as great as 6 to 7 log2, evident in
the HI titer for field strain 1709-6/2008, indicates major anti-
genic differences between the H5N2 vaccine strain and the
2008 Egyptian strain. This is in agreement with previous find-
ings using the same or genetically related 2007 and 2008 Egyp-
tian strains demonstrating within-clade antigenic variations
and drift among circulating H5N1 viruses (2, 7, 19, 30).
The results obtained with the MN assay revealed a 3- to
6-fold reduction of the neutralizing titer in the sera obtained
from vaccinated birds for field strain 1709-6/2008 compared to
1709-1/2007, consistent with the HI test results.
Genetic characterization of field (parental) viruses. The AA
sequence of the HA protein of the field strains showed that 12
AA substitutions occurred in the 2008 strain, 11 of which were
located in the mature HA1 subunit (Table 3). In 1709-6/2008,
all but one of the 11 AA substitutions were located in the
receptor binding subdomain (RBD) (9) in positions proximal
to the functional receptor binding site represented by the 190
-helix, the 130 loop, and 220 loop and a number of conserved
residues, such as Tyr98, Trp153, and His183 (6, 9, 26, 33, 42)
(Fig. 1 and Fig. 2). Out of the 11 AA substitutions detected, 4
(positions 140, 141, 162, and 184) were mapped to the corre-
sponding H3 antigenic sites A and B (Fig. 3) (14, 16, 23).
Interestingly, strain 1709-6/2008 exhibited AA mutations al-
most exclusively at positions where 1709-1/2007 and the H5N2
vaccine strain possessed the same AA (Table 3). Substitution
P74S, positioned outside the RBD, generates a potential ad-
ditional glycosylation site in 1709-6/2008, while substitution
TABLE 2. Microneutralization test results of chicken sera containing antibodies raised against the Mexican-derived H5N2 strain (sera 1 to 9),
A/Ck/Eg/1709-1/2007 (Ck Eg1) strain, A/Ck/Eg/1709-6/2008 (Ck Eg6) strain, and A/Avian/It/2000 H7N1 (Av H7N1) strain
Test antigen
Titer for serum:
1 2 3 4 5 6 7 8 9 Ck Eg1 Ck Eg6 Av H7N1 Negative
A/Ck/Eg/1709-1/2007 1,280 640 640 1,280 5,120 2,560 5,120 1,280 5,120 10,240 5,120 80 80
A/Ck/Eg/1709-6/2008 80 80 80 80 160 80 160 80 80 2,560 10,240 80 80
RG PR8Eg1 HANA 1,280 640 640 1,280 10,240 2,560 10,240 1,280 10,240 20,480 10,240 80 80
RG PR8Eg6 HANA 80 80 80 80 320 80 160 80 80 5,120 20,480 80 80
A/Avian/It/2000 H7N1 80 80 80 80 80 80 80 80 80 80 80 2,560 80
8720 CATTOLI ET AL. J. VIROL.
N165H in the same virus deletes a site for potential glycosyla-
tion (Fig. 1).
Generation and antigenic characterization of recombinant
viruses. RG reassortants included in this study are listed in
Table 1. These include the RG reassortants containing the
unmodified HA and NA of the 1709-1/2007 and 1709-6/2008
field strains (Table 1; mutants 4 and 3, respectively). In the test
system adopted in this study, they reacted very similarly to the
respective parental field strains, as demonstrated by the single
HI titers and by the mean geometric titer (MGT) in Table 1 as
well as by the results obtained using these RG reassortants as
antigens in the MN assay (Table 2).
To test their influence on immunogenicity and drift, the AA
substitutions located in proximity to the receptor binding site
and in major antigenic sites (mapped by genetic analysis or
predicted by computational analysis using the Kolaskar-Ton-
gaonkar method [5, 21; data not shown]) were selected for the
generation of RG reassortant mutants and subsequent testing
(Table 1). Substitution P74S, generating one potential addi-
tional glycosylation site in 1709-6/2008, did not produce signif-
icant variation when introduced in the HA protein of 1709-1/
2007 (mutant 6, Table 1). However, its deletion in the 1709-6/
2008 HA altered the antigenicity as highlighted by the moderate
to relevant increase in the HI titer (mutant 5, Table 1).
Introduction of substitutions at positions 140 and 141, singly
or in combination with P74S, produced an effect on antigenic-
ity (mutants 7 to 14, Table 1). The effects became progressively
more evident when two other AA substitutions were added,
particularly at positions 144 and 162 (mutants 15 to 22, Table
1). The antigenicity of mutant 4 and the respective field strain
1709-1/2007 was restored in mutant 17, harboring mutations at
positions 74, 140, 141, and 144 in the HA genetic backbone of
mutant 3 (Table 1). Mutants 20 and 22, with AA substitutions
at positions 74, 140, 141, 144, and 162 in the HA genetic
backbone of mutant 4, showed HI titers and MGTs similar to
mutant 3 and the respective field strain 1709-6/2008, indicating
that this minimum constellation of multiple substitutions pro-
duced major alterations in HA antigenicity and was responsi-
ble for the drift. Introduction of substitution A184E (e.g., mu-
tant 29; Table 1), located in close proximity to the 190 -helix
in 1709-6/2008, in the HA genetic backbone of mutant 4 also
altered the antigenicity, although variation was less pronounced
than in mutant 20. Introductions of other AA substitutions
(e.g., in positions 110 and 120) did not produce major effects.
DISCUSSION
In the present study, we have mapped and identified the
mutations of the HA protein involved in the antigenic drift
observable in the HPAI H5N1 variant virus which appeared in
Egypt in 2008 (strain 1709-6/2008). In addition, we have gath-
ered information suggesting that H5N1 virus evolution and
drift in vaccinated poultry are driven by mechanisms previously
described for human influenza viruses.
The sequence of the mature HA protein of strain 1709-6/
2008 differs from the HA of the selected 2007 virus (strain
1709-1/2007) by 11 amino acids, exclusively located in the HA1
protein. This is in line with previous findings which indicate 11
amino acid substitutions in the HA1 protein of these newly
emerging variants (1, 2). In 1709-6/2008, 10 out of 11 AA
TABLE 3. Amino acid differences in the HA1 protein between the











14 K E E
36 E T T
40 R K K
43 S D D
45 K D D
53 K R R
74 P P S
83 D I I
88 G D D
97 D N N
105 M L L
107 S R R
108 T I I
110 H H R
117 F I I
119 R K K
120 S N S
123 S S P
124 N D D
126 D E E
138 N Q Q
140 R R G
141 S S P
144 F F Y
154 N D D
156 V A A
158 Q P P
162 R R K
163 T S S
165 N N H
169 I I Q
174 I V V
184 A A E
188 I T T
189 K R R
195 N T T
198 V I I
209 S L L
210 I V V
212 E K K
217 P S S
226 M M V
234 R K K
235 P S S
238 S A A
240 T N N
244 T N N
252 Y N N
257 I V V
263 A T T
270 N E E
275 D N N
276 A T T
282 V I I
294 V I I
297 F L L
309 K N N
310 K R R
320 V S S
323 R G G
325 T R R
a In bold are shown the 11 amino acid differences between the strains A/ck/
Egypt/1709-1/07 and A/ck/Egypt/1709-6/08. The amino acid numbering used for
H3 in references 26 and 38 was adopted.
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substitutions were located in the receptor binding subdomain
close to the functional receptor binding sites at the globular
head of the protein (6, 9, 33, 42). RG-generated mutants of
1709-1/2007 demonstrated that 5 AA substitutions, at positions
74, 140, 141, 144, and 162, are primarily involved in the anti-
genic drift and that these mutations alone can reproduce the
antigenic vaccine drift observed for the 2008 field strain. The
opposite mutations introduced into the same sites in the HA
genetic backbone of 1709-6/2008 resulted in HI titers similar to
the 2007 strain, thus confirming the important role of these
AAs for the antigenic variation and drift (e.g., compare mu-
tants 17 and 18, 19 and 20, and 21 and 22; Table 1). Besides,
these results indicate that progressive accumulation of muta-
tions at multiple sites within the H5N1 HA1 molecule en-
hances antigenic drift and is necessary to increase the mutant
ability to escape polyclonal antibody response as revealed by
HI testing. This is in agreement with a previous study on H3N2
human influenza virus (32). Substitution P74S generates a po-
tential additional glycosylation site in 1709-6/2008, while sub-
stitution N165H in the same virus deletes a site for potential
glycosylation. HA glycosylation can affect receptor binding and
immune response and can modulate virulence of influenza
FIG. 1. Amino acid sequence alignment between HA proteins of A/chicken/Egypt/1709-6/2008, A/chicken/Egypt/1709-1/2007, A/chicken/
Mexico/232/94, and A/Viet-Nam/1203/04 strains. The figure shows the receptor binding subdomain (9) as a dashed line, the major 130 and 220
loops and 190 -helix as shaded squares, and amino acid differences between A/chicken/Egypt/1709-6/2008 and A/chicken/Egypt/1709-1/2007 as
smaller, unshaded squares.
FIG. 2. A/chicken/Egypt/1709-6/2008 HA monomer. Amino acid differences in the HA monomer between A/chicken/Egypt/1709-6/2008 and
A/chicken/Egypt/1709-1/2007 are shown in white; the major 130 and 220 loops and 190 helix are shown in magenta (image drawn with Pymol
software). The template protein was obtained by submitting the amino acid sequence of the HA protein to the structure homology modeling server
http://swissmodel.expasy.org. The Protein Data Bank accession codes obtained refer to influenza A virus (24) for the full monomer (Protein Data
Bank identification 2wr1A) and to strain A/Vietnam/1194/04 (41) for the portion from amino acid residue 1 to 340 (Protein Data Bank
identification 2ibX).
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viruses (36, 43). In the present study, the single substitution
P74S in the HA backbone of 1709-1/2007 did not alter the
antigenicity of this mutant significantly. In contrast, the dele-
tion of the potential glycosylation site (substitution S74P) in-
troduced in the HA genetic backbone of 1709-6/2008 increased
the MGT and HI titer, in some cases by a factor of 4 (Table 1).
This is consistent with previous findings indicating that single
selected substitutions in the HA protein may increase the HI
titer significantly (12). Additionally, substitution P74S intro-
duced together with R140G, S141P, F144Y, and R162K con-
tributed to the further reduction of the HI titer (e.g., compare
mutants 30 and 20, Table 1).
It is interesting that 3 out of 5 key amino acid substitutions
detected in this study (positions 140, 141, and 162) are located
in corresponding H3 antigenic sites A and B (16, 23). Muta-
tions in 6 positions of 1709-6/2008, namely, 110, 120, 123, 165,
184, and 226, do not appear critical for escape from antibody
binding. This could be explained by the fact that some of these
positions are either located outside major antigenic epitopes
(positions 110, 123, and 165) or not exposed to the surface of
the HA antigen (position 226) as predicted by the computa-
tional analysis (5, 8, 21).
The results obtained in this study indicate that antigenic drift
of H5N1 viruses in Egypt was initiated and driven by mutations
primarily occurring in the RBD and decreasing HI antibody
activities, similarly to what has been described for the antigenic
drift observed in human H1N1 and H3N2 influenza viruses
under experimental and field conditions (11, 15, 20). This is
also consistent with structural similarities in the antigenic sites
shared by H1, H3, and H5 subtypes (17, 18). The AA muta-
tions are located at the globular head of the HA1 protein in
proximity to functional binding sites, and some of the key
mutations are in the H3-corresponding A and B sites. These
sites contain functional epitopes with high neutralizing effi-
ciency (25). The HI and MN test results obtained in this study
are consistent with this observation. For H3N2 viruses, AA
changes of epitopes in antigenic sites A, B, and D could be
highly favored by natural selection in promoting the selection
of escape mutants, whereas changes in other epitopes might
not be advantageous for the virus (25). The immune pressure
on H5N1 viruses circulating in the vaccinated population likely
favored the generation of mutants harboring substitutions at
the globular head of the HA1 protein that alter the antigenic-
ity, resulting in lower HI antibody activities (i.e., lower HI
titer). Interestingly, our analysis demonstrated that the strain
which appeared in early 2008 did possess AA mutations exclu-
sively at positions shared between the previously circulating
strain (1709-1/2007) and the vaccine strain contained in one of
the vaccines most commonly used in Egypt (Table 3).
The major antigenic differences revealed by the HI assay in
viruses 1709-1/2007 and 1709-6/2008 were confirmed by the
MN assay, indicating that some of the key mutations identified
in this study are located in neutralizing epitopes. The appar-
ently conflicting data between in vitro (i.e., serological assays)
and in vivo (i.e., vaccine challenge) studies reported in previous
publications (12, 14, 35) deserve further investigations. Al-
though serological tests are extremely useful tools to screen
and identify the occurrence of antigenically drifted viruses, it
should also be considered that prediction of vaccine efficacy for
poultry based on in vitro assays may not correlate well with in
vivo challenge studies (30, 34). In this regard, factors related to
vaccine formulation, such as antigen content, vaccine dose, and
type of adjuvant, should be taken into account.
In regions of endemicity, reducing H5N1 virus circulation
through the administration of appropriate vaccines coupled
with the implementation of vaccination strategies in the animal
reservoir is essential to reduce the risk of human exposure and
the occurrence of viral mutations, which may have an unpre-
dictable impact on human health. The use of strongly adju-
vanted vaccines in poultry could partially overcome the need
for the accurate matching of vaccine strain in order to confer
satisfactory cross-protection and to increase vaccine efficacy
(19, 35). Previous publications suggested that extensive vacci-
nation of poultry for avian influenza can favor the emergence
of viruses antigenically drifted from the vaccines applied in the
field. This could potentially reduce vaccine efficacy and be
responsible for vaccination failures (2, 7, 22, 30, 34). Further-
more, factors other than the type of vaccine used (e.g., het-
erologous versus homologous vaccine strains) can contribute
to vaccination failures, such as quality of the vaccines and their
FIG. 3. A/chicken/Egypt/1709-6/2008 HA monomer. Amino acid differences in the HA monomer between A/chicken/Egypt/1709-6/2008 and
A/chicken/Egypt/1709-1/2007. In red are amino acid substitutions in antigenic site A (positions 140 and 141); in yellow are amino acid substitutions
in antigenic site B (positions 162 and 184). All the positions in white are the differences not included in the antigenic sites.
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proper storage and administration, the potential interference
of maternal antibodies, and vaccine coverage, as suggested or
demonstrated in previous publications (7, 11, 19, 28). All these
factors should be taken into account to better understand the
evolution of the virus and the mechanisms favoring its endemic
circulation in the poultry population.
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